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Anti-Mullerian-hormone-dependent regulation of the brain
serine-protease inhibitor neuroserpin
Abstract
The balance between tissue-type plasminogen activator (tPA) and one of its inhibitors, neuroserpin, has
crucial roles in the central nervous system, including the control of neuronal migration, neuronal
plasticity and neuronal death. In the present study, we demonstrate that the activation of the
transforming growth factor-beta (TGFbeta)-related BMPR-IB (also known as BMPR1B and Alk6)- and
Smad5-dependent signalling pathways controls neuroserpin transcription. Accordingly, we demonstrate
for the first time that anti-Mullerian hormone (AMH), a member of the TGFbeta family, promotes the
expression of neuroserpin in cultured neurons but not in astrocytes. The relevance of these findings is
confirmed by the presence of both AMH and AMH type-II receptor (AMHR-II) in brain tissues, and is
supported by the observation of reduced levels of neuroserpin in the brain of AMHR-II-deficient mice.
Interestingly, as previously demonstrated for neuroserpin, AMH protects neurons against
N-methyl-D-aspartate (NMDA)-mediated excitotoxicity both in vitro and in vivo. This study
demonstrates the existence of an AMH-dependent signalling pathway in the brain leading to an
overexpression of the serine-protease inhibitor, neuroserpin, and neuronal survival.
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Introduction
In the brain, tissue-type plasminogen activator (tPA, also known as
PLAT) is implicated in many physiological functions (Benchenane
et al., 2004; Samson and Medcalf, 2006) and in brain disorders
such as epilepsy, multiple sclerosis and stroke (Tsirka et al., 1995;
Tsirka et al., 1996; Wang et al., 1998; Nicole et al., 2001; Lu et al.,
2002).
The activity of serine proteases depends on their equilibrium
with serine-protease inhibitors, termed serpins, which generally
act as pseudo-substrates for their target proteases. Protease nexin
1 (PN1, also known as SERPINE2) and type-1 plasminogen
activator inhibitor (PAI-1, also known as SERPINE1) are the major
inhibitors of thrombin- and plasminogen-activators, respectively.
Neuroserpin (also known as SERPINI1) is another potent inhibitor
of the proteolytic activity of tPA, and to a minor extent of
urokinase-type plasminogen activator and plasmin, whereas it has
no effect on thrombin (Osterwalder et al., 1998). Unlike other
serpins, neuroserpin transiently complexes with tPA and thus acts
as a competitive substrate. In contrast to the ubiquitously expressed
PN1 and PAI-1, neuroserpin is almost exclusively expressed within
the brain and spinal cord during both development and adulthood
(Krueger et al., 1997).
tPA has been described to exert deleterious effects through its
proteolytic activity following excitotoxic brain injuries (Benchenane
et al., 2004), but these effects can be lessened by exogenous
neuroserpin (Lebeurrier et al., 2005). Moreover, neuroserpin
administration directly into the brain reduces ischemic lesions in
rats following permanent middle-cerebral-artery occlusion (Yepes
et al., 2000), whereas transgenic mice overexpressing neuroserpin
exhibit smaller ischemic infarcts than wild-type littermates (Cinelli
et al., 2001). The neuroprotective effect of neuroserpin following
cerebral ischemia could also be explained by its ability to prevent
the tPA-mediated blood-brain-barrier leakage (Zhang et al., 2002;
Yepes et al., 2003).
Although the transcriptional regulation of tPA or PAI-1 is well
described, that of neuroserpin is poorly characterized. In mouse
hippocampal neurons, elevated extracellular concentrations of KCl
induce neuroserpin gene transcription, whereas zif/268 (also known
as Krox-24 and EGR1) has a repressive effect (Berger et al., 1999).
Neuroserpin gene expression is also regulated at the level of RNA
stability by the binding of HuD (also known as ELAVL4; an RNA-
binding protein) to AU-rich sequences in its 3-UTR or by a thyroid
hormone (triiodothyronine, T3) in PC12 cells and in the rat brain
(Cuadrado et al., 2002; Navarro-Yubero et al., 2004). More recently,
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the neuroserpin promoter was reported to be placed head-to-head
with the programmed-cell-death-related gene PDCD10, leading to
a co-regulation of both genes (Chen et al., 2007).
Anti-Mullerian hormone (AMH), also named Mullerian
inhibiting substance (MIS), belongs to the transforming growth
factor-β (TGFβ) superfamily (Massague, 1998), and is known to
transduce its signals through serine/threonine type-II and type-I
receptors. To date, only the AMH type-II receptor (AMHR-II, also
known as AMHR2) has been identified (di Clemente et al., 2003);
the type-I receptor (AMHR-I) remains to be clearly identified.
Candidates for AMHR-I are the bone morphogenetic protein (BMP)
type-I receptors activin receptor-like kinase 2 (Alk2, also known
as ACVR1), Alk3 (also known as BMPR1A and BMPR-IA) and
Alk6 (also known as BMPR1B and BMPR-IB) (Josso et al., 2001;
di Clemente et al., 2003).
The aim of the present study was to reveal some elements of the
transcriptional regulation of neuroserpin in the brain. By using a
set of luciferase reporter genes for neuroserpin, we unexpectedly
identified AMH as a candidate regulator of neuroserpin expression.
Accordingly, by using primary cultures of cortical neurons and
AMHR-II-deficient mice, we revealed that AMH should now be
considered as a new regulator of neuroserpin expression and as a
neuroprotective factor.
Results
A Smad-responsive element controls the transcriptional
regulation of neuroserpin
The mink lung epithelial cell line (Mv1Lu) was transiently
transfected with the firefly luciferase reporter gene placed under
the control of various domains of the mouse neuroserpin promoter,
allowing us to identify several regulatory sequences within the
neuroserpin promoter (see Fig. 1 for details of the different
constructs). Luciferase activity (Luc) increased when the region
–1135 to –511 [LucC=454±87.40% versus LucD=1228.11±166.41%;
P<0.01], –511 to –346 (LucD=1228.11±166.41% versus LucE= 
3008.08±598.80%; P<0.01) or –78 to –24 (LucG=211.71±38.11%
versus Luc24=1687.69±335.11%; P<0.01) of the neuroserpin
promoter was absent. This finding suggests the presence of silencer
elements in each of these domains. By contrast, luciferase activity
decreased when the region –346 to –125 (LucE=3008.08±598.80%
versus LucF=1215±304.19%; P<0.05) or the regions –125 to –78
(LucF=1215±304.19% versus LucG=211.71±38.11%; P<0.01) was
absent. This result indicates the presence of enhancer elements in
these two regions of the neuroserpin promoter.
In order to establish a link between the domains identified above
and known responsive elements, a sequence analysis of the
neuroserpin promoter was performed using the Genomatix software.
Among the responsive elements identified, we noted that the E
construct (–346 to +72) contains a positive responsive element
between the positions –317 and –310, which matches the sequence
GTCTAGCC, previously described as a typical Smad-binding
element (SBE) that is crucial for TGFβ-family-mediated cell
responses (Dennler et al., 1998).
On the basis of these observations, Mv1Lu cells were transiently
co-transfected with the cDNAs encoding for mutated forms of the
type-I receptors for members of the TGFβ family [Alk proteins
carrying mutations that lead to the auto-activation of the receptor;
see Nakao et al., 1997 (Nakao et al., 1997)] and the A (full-length
promoter) or E (–346 to +72) constructs. BMPR-IA, BMPR-IB
and ActR-I (also known as ACVR1 and Alk2) are BMP type-I
receptors, whereas TGFβ and activin mediate their signal through
TβR-I (also known as TGFBR1 and Alk5) and ActR-IB (also
known as ACVR1B and Alk4) (Massague, 1998), respectively.
AMH mediates its signal through Alk2, Alk3 or Alk6 (di Clemente
et al., 2003) (Fig. 2D). The overexpression of Alk6 increased the
transcriptional activity of the E construct (LucE=99.92±1.86%
versus LucE/Alk6=809.67±86.47%; n=12; P<0.001) (Fig. 2A);
Alk3 and Alk4 enhanced the activity of the E construct to a weaker
extent. The other Alk proteins had no effect (Fig. 2A). Similarly,
Alk6 promoted the transcriptional activity of the full-length
neuroserpin promoter (LucA=99.96±3.49% versus
LucA/Alk6=701.83±153.90%; n=11; P<0.001) (Fig. 2B). The
other Alk proteins had no effect, apart from a slight transcriptional
activation of the neuroserpin promoter with Alk3 and Alk4 (Fig.
2B). These results suggest that the transcriptional activity of the
neuroserpin promoter could be potentially enhanced both by BMPs
and AMH, and to a lesser extent by TGFβ and activin.
All receptors for the TGFβ family are known to mainly transduce
their signals through the activation of Smad-dependent signalling
pathways. Thus, we transiently co-transfected Mv1Lu cells with
expression vectors encoding for different members of the Smad
family and the E construct. Smad2 and Smad3 are specific mediators
of the TGFβ and activin pathways, whereas Smad1, Smad5 and
Smad8 are involved in BMP signalling (Massague, 1998) and AMH
signalling (di Clemente et al., 2003) (Fig. 2D). Among the different
Smad proteins that were tested, only Smad5 significantly increased
the transcriptional activity of the E construct (LucE=100.40±1.83%
versus LucE/Smad5=205.98±21.52%; n=11; P<0.001) (Fig. 2C).
These data highlight BMPs and/or AMH as potential regulators of
the transcription of the neuroserpin gene.
AMH controls the cerebral expression of neuroserpin both in
vitro and in vivo
Based on the foregoing results, the influence of recombinant BMPs
and/or AMH on neuroserpin gene expression was investigated by
Journal of Cell Science 121 (20)
Fig. 1. Analysis of the putative mouse neuroserpin promoter. Regions of the
putative mouse neuroserpin promoter were subcloned into pGL3-Basic vector,
upstream of the firefly luciferase gene. Mv1Lu (mink lung epithelial) cells
were transiently transfected with the pRL-TK control vector and pGL3-Basic
vector containing the different regions of the mouse neuroserpin promoter.
Firefly and Renilla luciferase activities were measured as described in the
Materials and Methods. After normalization to Renilla luciferase activity,
values were expressed as a percentage of the activity of construct A (valued as
100%) (mean ± s.d.; n=8). Asterisks indicates a significant difference from the
A construct: *P<0.05, **P<0.01, ***P<0.001; hash marks indicate a
significant difference from the E construct: #P<0.05, ##P<0.01; Kruskall-
Wallis test followed by a Mann-Whitney post-hoc test.
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3359Transcriptional regulation of neuroserpin by AMH
quantitative reverse-transcriptase (RT)-PCR both in murine cultured
cortical neurons and astrocytes. Under basal conditions, both
neurons and astrocytes displayed mRNA for the serine protease tPA
and its endogenous inhibitors neuroserpin, PN1 and, to a lesser
extent, PAI-1 (Fig. 3A).
Primary cultures were then treated with
recombinant BMPs (BMP2, BMP4 and BMP7), at
a dose of 1 or 10 ng/ml, over 24 hours. Whereas
BMP4 and BMP7 had no significant effect in both
cell types (Fig. 3B; Fig. 4), BMP2 selectively
upregulated neuroserpin transcription (Fig. 3B) but
not neuroserpin translation (Fig. 4) in neurons, with
no effect in astrocytes.
Primary cultures were then exposed to recombinant AMH (1 or
10 ng/ml) for 24 hours in serum-free medium. In cultured cortical
neurons, AMH (10 ng/ml) doubled the transcription of the
neuroserpin gene (n=5; P<0.01) (Fig. 3B) whereas, in astrocytes,
there was a tendency towards activation, but that did not reach
statistical significance (n=3) (Fig. 3B). AMH also failed to promote
the expression of mRNA encoding for the programmed-cell-death-
related gene PDCD10, a gene that was recently demonstrated to be
linked by an asymmetric bidirectional promoter to neuroserpin
(Chen et al., 2007) (data not shown). In agreement with the PCR
analyses, immunoblots that were performed on cell monolayers
revealed that, in cultured cortical neurons, AMH increased
neuroserpin protein levels by 50% after 24 hours (Fig. 4) (n=11;
P<0.01).
The expression of neuroserpin was also investigated in several
brain structures (cortex, striatum, hippocampus) of AMHR-II-
deficient mice (heterozygous and homozygous deficient animals)
and wild-type littermates (Fig. 5). Quantitative RT-PCR revealed
that AMHR-II deficiency led to reduced cerebral levels of mRNA
encoding for neuroserpin in these structures (i.e. ~35% in the cortex;
n=6-12; P<0.05) (Fig. 5). Because AMH is known to control sexual
maturation (Josso et al., 1998; Josso and di Clemente, 1999), the
effect of endogenous AMH on the control of brain neuroserpin
expression was investigated in both males and females. Gender did
not affect the expression of neuroserpin in the adult brain (see
supplementary material Fig. S1).
Altogether, these data demonstrate that AMH is a regulator of
the neuronal expression of neuroserpin both in vitro and in vivo.
AMHR-II receptors are expressed in the developing and adult
brain
To determine whether AMHR-II is expressed in the brain,
immunohistochemistry with previously characterized antibodies
(Gouédard et al., 2000) was performed on mouse embryos (E16,
corresponding to the developmental stage from which cultures of
cortical neurons were obtained) and adult mice. Immunostaining
for BMPR-II was performed in parallel in order to check that the
antibody used against AMHR-II did not crossreact with BMPR-II.
Antibodies revealed different specific antigens both in the brain (see
Fig. 2. AMH promotes the transcription of neuroserpin. (A,B,C) Mv1Lu cells
were transiently transfected with the pRL-TK control vector and pGL3-Basic
vector containing the E (–346 to +72) or A (–3941 to +72) constructs. At the
same time, cells were co-transfected with pcDNA3 containing the cDNA
encoding for either auto-activated versions of type-I receptors for members of
the TGFβ family (Alk proteins, A,B) (n=11-12) or proteins of the Smad family
(C) (n=8). Luciferase activities were measured as described in Materials and
Methods. Values are indicated as a percentage of the activity in controls (–; E
or A reporter vector co-transfected with the empty pcDNA3 vector). Bars
represent mean values ± s.d. **P<0.01, ***P<0.001; Kruskall-Wallis test
followed by Mann-Whitney posthoc test. (D) Summary of the Alk and Smad
proteins involved in intracellular signalling pathways of the TGFβ family
members TGFβ, BMP and AMH.
Fig. 3. Regulation of neuroserpin expression in vitro.
(A) mRNA levels of neuroserpin (NS), tPA, PAI-1 and
protease nexin 1 (PN1) in cultured neurons (N; n=3) and
astrocytes (A; n=3). (B) Evaluation of the mRNA levels for
neuroserpin in cultured neurons (n=5) and astrocytes (n=3)
treated over 24 hours with either recombinant BMP2, BMP4,
BMP7 or AMH at a concentration of 1 or 10 ng/ml. Relative
levels of mRNA expression were measured by quantitative
PCR as described in the Materials and Methods. C, control.
Results were computed by calculating both the 2–ΔCt (white
bars) and the 2–ΔΔCt (grey bars). Bars represent mean values
± s.d. (2–ΔCt: *P<0.05, **P<0.01; 2–ΔΔCt: #P<0.05, ##P<0.01;
Kruskall-Wallis test followed by Mann-Whitney post-hoc
test).
Jo
ur
n
a
l o
f C
el
l S
cie
nc
e
3360
supplementary material Fig. S2B,D,F) and the testes (see
supplementary material Fig. S2A,C,E). Thus, we first studied the
expression pattern of AMHR-II in the mouse telencephalic wall at
E16. We observed that the AMHR-II immunostaining (TRITC) was
associated with the developing ventricles (Fig. 6A-D), especially
the ventricular cell layer and the surrounding subventricular zone
(Fig. 6C,D). In the adult mouse (C57Bl6/J and Swiss) brain,
immunostaining for AMHR-II (TRITC) was mainly associated with
brain capillaries (Fig. 7A-D). AMHR-II-positive staining was also
localized in the cortical (Fig. 7A-D) and hippocampal (Fig. 7E,F)
parenchyma, with an intense staining around large vessels of the
stratum lacunosum molecularis (SLM) (Fig. 7E), in which the
density of glial cells is known to be high (Shimada et al., 1991).
Fig. 7F illustrates AMHR-II-positive staining in glial cells (white
arrows). In addition, AMHR-II immunoreactivity was also noted
along nerve fibres (as illustrated by neurofilament-positive staining,
Fig. 7D) (NF: FITC) in the cortex (Fig. 7C,D), but also in the
cerebellum (see supplementary material Fig. S3A) and the corpus
callosum (see supplementary material Fig. S3B), suggesting the
presence of AMH-RII immunoreactivity in adult neuronal cells.
The expression pattern of AMH and AMHR-II in the brain was
further characterized by quantitative RT-PCR that was performed
on RNAs harvested from either primary cultures [neurons at 2 or
14 days in vitro (DIV), astrocytes and brain-derived endothelial
cells] or nervous-system structures (cortex and spinal cord from
neonatal or adult mice; Table 1). Positive expression of TβR-II
(also known as TGFBR2; one of the two receptors known to
transduce TGFβ1 signalling) and of TGFβ1 were investigated 
in parallel. The findings show that, similar to TβR-II
(CtNeuron 14DIV=27.0±0.4; Ct denotes threshold cycle), AMHR-II
is expressed in neurons (CtNeuron 14DIV=29.3±1.0). Cultured
astrocytes and, to a lesser extent, cultured brain endothelial cells
(Table 1) also exhibit AMHR-II. mRNA encoding for AMHR-II
were also detected in the neonatal (P7) and adult brain cortex. As
previously described (Wang et al., 2005), AMHR-II is also
expressed in the spinal cord from neonatal and adult mice.
Although the levels of mRNA encoding for AMHR-II were
significantly different in neonatal mice with respect to gender, no
such effect of sex was observed in adult mice (Table 1).
The expression of AMH mRNA was also investigated in cultured
cells and tissues. Cultured neurons, astrocytes and brain endothelial
cells displayed mRNA encoding for AMH as they did for TGFβ1
(in neurons at 14 DIV: CtAMH=28.7±0.8 versus CtTGFβ1=27.3±0.3).
AMH was also expressed in cortices from neonatal and adult mice.
In the spinal cord, AMH expression was lower in adult mice than
in neonatal mice. Interestingly, both neonatal and adult female mice
displayed a lower expression of AMH in the cerebral cortex than
did their male counterparts. This gender effect was also true for
neuroserpin mRNA in neonatal mice (Table 1).
AMH protects neurons against NMDA-mediated excitotoxicity
Because neuroserpin was previously demonstrated to protect
neurons from NMDA-mediated death both in vitro and in vivo
(Lebeurrier et al., 2005), we hypothesized that, if AMH actually
promotes neuroserpin expression, it should also be able to exert a
neuroprotective activity. First, primary cultures of cortical neurons
that were subjected to NMDA-induced excitotoxic neuronal death
were thus treated with increasing doses of recombinant AMH (1-
10 ng/ml) (Fig. 8A). Although NMDA alone induced around 50%
neuronal death, co-application of recombinant AMH at 10 ng/ml
led to a significant reduction of NMDA-induced neuronal death
(65% reduction), as previously reported for neuroserpin. Similarly,
in a model of excitotoxic neuronal death in mice, induced following
intrastriatal injection of NMDA (10 nmol) (Fig. 8B), co-injection
of recombinant AMH (0.45 pg) led to a reduction of around 35%
of lesion volume (P<0.01).
Discussion
Although the cerebral distribution of the neuroprotective serpin
neuroserpin is well characterized, its transcriptional regulation is
poorly documented. Neuroserpin is expressed in the developing and
adult nervous system (Krueger et al., 1997). In situ hybridization
has previously revealed a neuronal expression during the late stages
of neurogenesis and, in the adult brain, in regions that exhibit
synaptic plasticity (Osterwalder et al., 1996). During embryonic
development, neuroserpin is expressed in several central nervous
system (CNS) regions. In the cerebellum, the granule cells and a
subgroup of Purkinje cells display neuroserpin during postnatal
development (Krueger et al., 1997). In the adult CNS, neuroserpin
Journal of Cell Science 121 (20)
Fig. 4. AMH promotes the expression of the protein neuroserpin in cultured
neurons. (A) Neurons were treated during 24 hours with either recombinant
BMP2 (n=9), BMP4 (n=6), BMP7 (n=3) or AMH (n=7) at the concentration of
1 ng/ml. Immunoblots were revealed with an antibody raised against mouse
neuroserpin [antibody G64 (Lebeurrier et al., 2005)]. (B) Densitometries of
immunoblots performed with ImageJ software. Bars represent mean values ±
s.d. **P<0.01; Kruskall-Wallis test followed by Mann-Whitney post-hoc test.
Fig. 5. Expression of neuroserpin in AMHR-II-deficient mice. Evaluation of
the mRNA levels of neuroserpin (NS) in the cerebral cortex, hippocampus and
striatum of C57Bl6/J mice. Mice strains are wild type (WT; n=7-12), or
heterozygote (HT; n=7-11) or homozygote (KO; n=6) AMHR-II deficients.
Results were computed by calculating both the 2–ΔCt (open bars) and the 2–ΔΔCt
(filled bars). Symbols indicate significant difference from wild-type mice
(2–ΔCt: **P<0.01; 2–ΔΔCt: ##P<0.01); Kruskall-Wallis test followed by Mann-
Whitney post-hoc test.
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3361Transcriptional regulation of neuroserpin by AMH
is expressed in the neocortex, hippocampus, olfactory bulb and
amygdala (Hastings et al., 1997). Expression of neuroserpin has
also been reported in the spinal cord (Osterwalder et al., 1996;
Hastings et al., 1997; Krueger et al., 1997). Our present data are in
agreement with these previous reports. Regarding its transcriptional
regulation, the level of neuroserpin mRNA is increased in cultured
hippocampal neurons upon depolarization (Berger et al., 1999).
Using luciferase reporter constructs that contained segments of the
promoter region of the neuroserpin gene, Berger and collaborators
identified a 200-bp segment, near the transcription initiation site,
that was responsible for both the neuron-specific expression and
the enhanced transcription following depolarization. Similarly,
neuroserpin mRNA and protein expression are induced by the
thyroid hormone in rat PC12 cells (Cuadrado et al., 2002; Navarro-
Yubero et al., 2004). Although there is no direct effect on the
transcription rate, the neuroserpin mRNA half-life is increased
Fig. 6. Distribution of AMHR-II immunoreactivity in the developing forebrain
of E16 mouse embryos (coronal sections). (A-D) AMHR-II immunoreactivity
(TRITC) is detected in the neuroepithelium of the ventricular zone (arrows).
AMHR-II immunoreactivity is also detected in the developing parenchyma (*
in B). Higher magnifications of the boxed region in B and C (C and D,
respectively) show that the AMHR-II immunostaining is mainly confined to
the ventricular zone (VZ) and the subventricular zone (SVZ). (B-D) Nuclei are
counterstained with DAPI (blue). di, diencephalon; iz, intermediate zone; mz,
marginal zone. Scale bars: 500 μm (A); 200 μm (B); 50 μm (C); 20 μm (D).
Fig. 7. AMHR-II immunostaining in adult mouse brain. In the cortex,
immunostaining for AMHR-II (TRITC) is predominantly associated with
capillaries (arrows in A-D) and the external zone of the cortical layer
(arrowheads in A and B), with a weaker immunostaining in the parenchyma. In
the cortex, AMHR-II immunostaining is associated with cortical nerve fibres
(arrowheads in C and D), which are positive for the 160-kDa neurofilament
(insert in D). In the hippocampus (E), immunostaining for AMHR-II (TRITC)
is observed in the parenchyma surrounding the large vessels of the stratum
lacunosum molecularis (SLM). At higher magnification (F), the perivascular
AMHR-II immunoreactivity is associated with glial cells (arrows) and, more
precisely, astrocytes, which are characterized by GFAP immunoreactivity
(inserts in F). The nuclei are counterstained with DAPI (blue; A-F).
Table 1. Expression of AMHR-II, AMH and neuroserpin in the central nervous system
AMH-RII AMH TβR-II TGFβ Neuroserpin 
Cultures Neurons 2 DIV 28.9±0.81 27.6±0.43 26.77±0.34 25.79±0.52 –
14 DIV 29.35±1.01 28.72±0.77 27.04±0.37 27.3±0.3 23±0.49
Astrocytes – 29.08±0.34 30.51±0.57 – – 25.64±0.54
Endothelial cells From P10 33.08±1.13 29.78±0.45 – – –
From adult 33.38±0.79 29.86±0.34 – – –
Microvessels From P10 31.11±1.24 29.88±0.13 – – 27.28±0.41
From adult 30.82±1.64 29.16±0.78 – – 26.23±0.48
Neonatal mice (P7) Cortex Male 29.64±0.62 31.11±0.45 – – 22.48±0.46
Female 31.29±1.2 33.12±1.55 – – 24.52±1.67
Spinal cord Male 30.91±0.38 31.34±0.66 – – 22.63±0.63
Female 31.75±0.58 31.87±0.71 – – 24.11±0.95
Adult mice Cortex Male 29.89±0.27 31.27±0.48 27.94±0.25 26.6±0.37 22.13±0.51
Female 29.69±0.37 32.27±0.58 27.66±0.29 26.06±0.13 21.63±0.45
Spinal cord Male 28.09±1.12 35.06±2.34 – – 26.39±0.66
Female 28.32±1.03 34.17±2.09 – – 27.59±1.29
Evaluation of mRNA levels of AMHR-II, AMH, TβR-II, TGFβ and neuroserpin in either cultured cells such as neurons (2 or 14 DIV, n=3), astrocytes and
endothelial cells (from P10 or adult Swiss mice, n=3-4), or in nervous tissue such as cerebral cortex and spinal cord (from P7 or adult Swiss mice; males or
females; n=6 per group), and in microvessels (from P10 or adult Swiss mice; n=3). The values (± s.d.) correspond to the mean threshold cycle (Ct).
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following binding of a cytoplasmic protein, the RNA-binding
protein HuD, to the neuroserpin 3-UTR, leading to an increased
accumulation of neuroserpin mRNA (Cuadrado et al., 2002;
Navarro-Yubero et al., 2004). In the present study, we provide
evidence that a 5 regulatory element (–317 to –310) of the rat
neuroserpin promoter, characterized as a Smad-binding element
(SBE), positively controls the transcription of neuroserpin. Indeed,
transient transfection of either auto-activated Alk6 or Smad5 in
Mv1Lu cells leads to an increased transcriptional response of the
neuroserpin promoter. In our hands, although our data are in
agreement with those published by Berger et al. (Berger et al., 1999)
and demonstrate the presence of an enhancer region of 200 bp near
the transcription initiation site of the neuroserpin promoter, they
differ from an earlier study (Chen et al., 2007) that reported a
repressive regulatory element in position 176-473, which was absent
in our system. These latter discrepancies could be due to species
differences (murine versus human) and/or to the type of cell line
used for reporter-gene experiments. Accordingly, we demonstrate
that AMH, a member of the TGFβ superfamily, regulates the
expression of neuroserpin in neurons but not in astrocytes,
supporting previous reports suggesting that neurons are the major
source of neuroserpin in the CNS (Krueger et al., 1997). Although
astrocytes display AMHR-II, neuroserpin transcription was weakly
induced by AMH, but not to levels reaching statistical significance.
Among other explanations, one can hypothesize that additional
elements in the transduction of AMH signal (such as the associated
AMHR-I) might lack in astrocytes, and/or that these cells
alternatively express inhibitory factors (repressive transcription
factors, inhibitory Smads etc.). Our in vivo data obtained from
AMHR-II-deficient-mice confirm the relevance of the
transcriptional regulation of brain neuroserpin by AMH.
BMPs and AMH are members of the TGFβ superfamily, which
includes over 25 members in mammals. Several of these members
have been reported to be expressed in the CNS, such as TGFβ
(Vivien and Ali, 2006) and BMPs (Ebendal et al., 1998). TGFβ and
BMPs mediate their signal via different hetero-oligomeric
complexes of type-I and type-II serine/threonine kinase receptors.
The adult brain exhibits most of these receptors, including high
levels of BMP receptor type II, TGFβ receptors type I and II, and
activin receptors type I and II (Ebendal et al., 1998; Vivien and Ali,
2006). These observations suggest that TGFβs (TGFβ1, TGFβ2 and
TGFβ3), osteogenic protein 1 (also known as OP-1 and BMP7),
BMP2 and BMP4 exert a specific neuronal function. AMHR-II has
been identified and cloned (di Clemente et al., 2003); however, no
clear AMHR-I has been reported so far (Josso et al., 2001; di
Clemente et al., 2003). Intracellular signalling mediating
responsiveness to AMH involves BMP-like signalling pathways
such as recruitment of the transcription factors Smad1, Smad5 and
Smad8 (Josso et al., 2001; di Clemente et al., 2003). Although AMH
signalling has been reported to play a crucial role during sex
differentiation and gonadal functions (Josso et al., 1998; Josso and
di Clemente, 1999), a recent report suggests that AMH-dependent
signalling could control the survival of motor neurons (Wang et al.,
2005). Accordingly, the presence of AMHR-II was demonstrated
in motor neurons (Wang et al., 2005). We now provide evidence
that cerebral neurons also exhibit AMHR-II (mRNA and protein)
both in vitro and in vivo. Interestingly, AMHR-II was also detected
in brain microvessels and to a lesser extent in cultured endothelial
cells. Although the ligand of this receptor, AMH, was initially
reported to be expressed by both Sertoli cells in the testes (Josso,
1973) and in granulosa cells in ovaries (Vigier et al., 1984), it was
also recently described in the spinal cord (Wang et al., 2005). Here,
we thus extend these works by showing that the mRNA encoding
for AMH is also expressed in the brain parenchyma.
One of the main roles of neuroserpin in the CNS is the control
of the proteolytic activity of the serine protease tPA. Serine
proteases are a superfamily of proteins in which most members were
initially described for their functions in relation to coagulation and
thrombolysis (Lijnen and Collen, 1997). In addition to their presence
in the blood, several serine proteases, including tPA, have been
identified in the CNS. Within the brain parenchyma, tPA is
synthesized by neurons and glial cells (Buisson et al., 1998;
Rogove and Tsirka, 1998). tPA is now considered as a positive
neuromodulator of the glutamatergic signalling involved in learning
and memory processes (Qian et al., 1993; Huang et al., 1996;
Fernandez-Monreal et al., 2004a; Samson and Medcalf, 2006) and
in some neurodegenerative diseases (Melchor et al., 2003). For
example, it was shown that tPA can interact with the NMDA receptor
and thus potentiates excitotoxic neuronal death (Nicole et al., 2001;
Fernandez-Monreal et al., 2004b). Accordingly, tPA inhibitors, such
as PAI-1 and neuroserpin, are able to counteract this deleterious
effect of tPA in the brain. For example, studies have revealed that
Journal of Cell Science 121 (20)
Fig. 8. Neuroprotective effect of AMH against NMDA-induced excitotoxicity.
(A) Pure cultures of neurons (14 DIV) were exposed for 24 hours to NMDA
(12.5 μM) without (black bars) or with (white bars) increasing concentrations
of AMH (1 or 10 ng/ml) and neuronal death was measured as described in the
Materials and Methods (n=4). Asterisks indicate a significant difference from
NMDA alone by one way Kruskall-Wallis test followed by Mann-Whitney
post-hoc test (*P<0.05). (B) Effects of intra-striatal injection of recombinant
AMH (0.45 pg) on the extent of neuronal death induced by the striatal
administration of NMDA (10 nmol) in mice (n=9). Bars represent mean values
± s.e.m. **P<0.01; Mann-Whitney test. Diagram on the right illustrates on a
brain section the typical lesion size obtained by the striatal injection of NMDA
alone versus NMDA + AMH.
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PAI-1 can prevent the harmful effect of tPA against excitotoxic or
ischemic brain injuries (Nagai et al., 1999; Nicole et al., 2001;
Benchenane et al., 2005). Similarly, neuroserpin was shown to be
neuroprotective in a rat model of stroke (Yepes et al., 2000) and to
promote survival of motor and cortical neurons (Simonin et al.,
2006; Lebeurrrier et al., 2005). In agreement with these observations
and with the recent demonstration that AMH-dependent signalling
could also control the survival of motor neurons (Wang et al., 2005),
we evidence here that AMH protects neurons against NMDA-
mediated excitotoxicity both in vitro and in vivo. Although we
cannot rule out the possibility of other mechanisms, all our data
strongly suggest that AMH-induced expression of neuroserpin in
neurons could sustain a neuroprotective pathway against NMDA-
receptor-mediated excitotoxicity.
In conclusion, we evidence that AMH should now be considered
as a new cytokine or hormone in the brain, with the serine-protease
inhibitor neuroserpin as one of its target genes, which could confer
neuroprotection against excitotoxicity.
Materials and Methods
Reporter-gene assay
The Dual-luciferase Reporter Assay System (Promega, France) refers to the
simultaneous expression and measurement of two individual reporter enzymes (firefly
luciferase and Renilla luciferase) within a single system. The pRL-TK vector
containing the herpes simplex virus thymidine-kinase promoter region (upstream of
Renilla luciferase) was used as a control for transfection efficiency. The background
bioluminescence level was measured in cells transfected with empty vectors (pGLl3-
Basic with, or without, pCDNA-3). The firefly luciferase activities were normalized
to the Renilla luciferase activity in order to minimize experimental variability. The
different fragments of the mouse neuroserpin promoter were sub-cloned to the pGL3-
Basic vector containing the firefly luciferase cDNA as described previously (Berger
et al., 1999). In order to fuse a DNA fragment of the neuroserpin gene with the
luciferase cDNA, a 150-bp blunt-ended AvaI fragment (–78 to +72 relative to the
transcription initiation site) was cloned to the blunt-ended BglII-HindIII-cut pGL3-
Basic vector to produce the precursor construct pGL378bp. Then, luciferase reporter
plasmids were obtained following insertion of a series of neuroserpin promoter regions
in between appropriate restriction sites, leading to the generation of the following
set of constructs: A (–3941 to +72), B (–2724 to +72), H (–2088 to +72), Sta (–1410
to +72), C (–1135 to +72), D (–511 to +72), E (–346 to +72), F (–125 to +72), G
(–78 to +72) and –24 (–24 to +72).
Primary neuronal cultures
Primary neuronal cortical cultures were prepared from mouse embryos (E15-E16).
After dissection and dissociation in Dulbecco’s modified Eagle’s medium (DMEM;
Sigma), cortices were plated on 24-well plates coated with 0.1 mg/ml poly-D-lysine
(Sigma) and 0.02 mg/ml laminin (Invitrogen). Cells were cultured in a DMEM
supplement containing 5% foetal bovine serum (FBS; Gibco), 5% horse serum (Gibco)
and 2 mM glutamine (Sigma). Cultures were maintained at 37°C in a humidified 5%
CO2 atmosphere. Cytosine β-arabinoside furanoside (10 μmol/l) was added after 3
days in vitro (3 DIV) in order to inhibit non-neuronal proliferation. After 12 DIV,
cultured neurons were treated with recombinant human BMP2, BMP4, BMP7 (R&D
Systems) and AMH (Picard and Josso, 1984; Picard et al., 1986) at doses of 1 and
10 ng/ml and studied at 24 hours.
Primary astrocyte cultures
Cell cultures of cortical astrocytes were prepared from mouse pups (1-3 days after
birth) using DMEM supplemented with 2 mM glutamine, 10% horse serum and 10%
FBS. Every 3 days the cells (maintained at 37°C in a humidified 5% CO2 atmosphere)
were washed with a phosphate buffer saline (PBS) solution in order to eliminate
microglial cells. When cultures were confluent (8-10 DIV), treatment was performed
with recombinant human BMP2, BMP4, BMP7 (R&D Systems) and AMH (Picard
and Josso, 1984; Picard et al., 1986) at doses of 1 and 10 ng/ml and studied at 24
hours.
Brain microvessels and primary cultures of mouse brain
endothelial cells
Brain microvessel endothelial cells (BMECs) were prepared from 10-day-old or 5-
week-old mice (Swiss NMRI; JANVIER, France). Cortices free from meninges and
outer vessels were homogenized in a Dounce tissue homogenizer in MCDB131
supplemented with 2% FBS, and 100 U/ml penicillin and 100 μg/ml streptomycin.
After centrifugation at 200 g for 10 minutes, the pellet was suspended in 18% (wt/vol)
dextran solution (Sigma) and centrifuged at 2000 g for 45 minutes at 4°C. The pellet
was then suspended in MCDB131 and filtered through 70-μm-cell strainer (Falcon,
BD Biosciences). The resulting filtrate was digested at 37°C in MCDB131 with 2%
FBS, and 0.5 mg/ml collagenase-dispase and 100 μg/ml DNase I (Roche Diagnostics,
France). The digested fragments were incubated at room temperature with anti-murine
PECAM-1 (MEC 13.3; BD Pharmingen)-precoated Dynabeads (Dynal, Invitrogen)
for 30 minutes in MCDB131 containing 0.1% FBS. Bead-bound microvessel
fragments were collected using a magnetic particle concentrator (MPC-S; Dynal,
Invitrogen) and washed three times with PBS. Thereafter, microvessels were lysed
for RNA extraction or plated (to obtain MEC monolayers) onto murine collagen type
IV (50 μg/ml; BD Biosciences) in MCDB131 supplemented with 10% FBS, 10%
HS, 100 U/ml penicillin and 100 μg/ml streptomycin, 2 mM L-glutamine, 10 ng/ml
VEGF165 (R&D Systems), and bFGF (Invitrogen). The cultures were incubated at
37°C in a humidified atmosphere of 5% CO2. After 24 hours, adherent cells were
washed with PBS to remove the magnetic beads and exposed to fresh medium, which
was changed every 2 days. At confluence (3-5 DIV), cells were lysed for RNA
extraction. Endothelial cells derived from 10-day-old or 5-week-old mice were
characterized by a cobblestone-like or spindle-shaped morphology, showed an uptake
of acetylated low-density lipoprotein labelled with 1-1dioctadecyl-3,3,3,3-
tetramethylindocarbocyanine perchlorate (DiL-Ac-LDL) and were immunoreactive
for PECAM and Von Willebrand factor.
Animals
We used neonatal (P7) and adult Swiss mice (Janvier, France); AMHR-II-deficient
C57Bl6/J mice (Mishina et al., 1996), and corresponding wild-type and heterozygous
littermates.
Quantitative real-time reverse-transcriptase PCR
Total RNAs were extracted from cultured cells or tissues using the NucleoSpin RNA
II kit (Macherey-Nagel, France) and from the adult spinal cord with the RNeasy
Lipid Tissue kit (Qiagen). RNA (1 mg) was reverse-transcribed (42°C; 1 hour) using
the Promega RT system (Promega, France). The specificity of the designed primers
(Beacon Designer software; Bio-Rad, France) was checked with the Blast database.
The following primer sequences were used: tPA forward primer (F), 5-
CTCCGACCCATGCTCAGAA-3; tPA reverse primer (R), 5-TTGTA -
CCAGGCCGCTGTTG-3; neuroserpin (F), 5-CGCCATTCAATGGGATATG-3;
neuroserpin (R), 5-CAAAGAGCGAATTGGCAAG-3; PAI-1 (F), 5-CGCT -
GCACCCTTTGAGAAAG-3; PAI-1 (R), 5-GGGCAGCCTGGTCATGTT-3;
protease nexin 1 (PN1) (F), 5-TGTGTTTCAGTGTGAAGTGCAGAA-3; PN1 (R),
5-CGATCAGATTTGGGGAAAGCAGAT-3; AMH (F), 5-ACCCTGG -
TGGTGCTGCCA-3; AMH (R), 5-AAGCGAGTGAGGGTCTCTAGGA-3;
AMHR-II (F), 5-CAGGGCTGCCCAGAGAACTG-3; AMHR-II (R), 5-
TTGCTGAACACTGAGGAGACAAG-3; cyclophilin A1 (F), 5-CAGGGTG -
GTGACTTTACACGC-3; cyclophilin A1 (R), 5-TGTTTGGT -
CCAGCATTTGCCA-3; β-actin (F), 5-ATCTACGAGGGCTATGCTCTCC-3; β-
actin (R), 5-CCACGCTCGGTCAGGATCTT-3; GAPDH (F), 5-
CCAATGTGTCCGTCGTGGATC-3; GAPDH (R), 5-GCCCTCAG ATGCC -
TGCTTCA-3; β2-microglobulin (F), 5-GCCGAACATACTGAACTGCTAC-3;
β2-microglobulin (R), 5-GCTGAAGGACATATCTGACATCTC-3. Two negative
controls were performed: samples without reverse transcription, and RNase-free water
instead of cDNA to control DNA contamination in samples and reagents. Assays
were run using IQ SYBER Green Supermix (Bio-Rad, France) and the iCycler iQ
real-time PCR detection system (Bio-Rad). Amplification conditions were: Hot
Goldstar enzyme activation, 95°C for 3 minutes; 50 cycles at 95°C for 15 seconds
and at 60°C for 1 minute. The levels of expression of interest gene were computed
as follows: 
relative mRNA expression = 2–(Ct of gene of interest), 
where Ct is the threshold-cycle value. They were also computed with respect to the
mRNA expression level of the reference gene transcript using the formula: 
relative mRNA expression = 2–(Ct of gene of interest – Ct of gene of reference) .
Immunoblotting
Cells were lysed in cold Tris-NaCl-Triton buffer containing 1% of protease inhibitor
cocktail (Sigma) and were centrifuged (20 minutes; 10,000 g; 4°C). Proteins were
quantified using a BCA protein assay (Pierce). Proteins (60 μg) were separated by
10% SDS-PAGE and transferred onto a PVDF membrane. Membranes were blocked
with Tris-buffered saline (TBS: 10 mM Tris and 200 mM NaCl, pH 7.4) containing
0.05% Tween-20, 5% dry milk. Blots were exposed overnight to the mouse
neuroserpin primary antibody G64 (1:1000; 4°C) (Lebeurrier et al., 2005), then to
the goat biotin-conjugated secondary antibody (1:10,000) and finally peroxidase-
conjugated streptavidin (1:5000). Proteins were visualized with an enhanced
chemiluminescence ECL-Plus detection system (Perkin Elmer-NEN, France).
Single- or double-labelled immunohistofluorescence methods
Deeply anesthetized (500 mg/kg of chloral hydrate) adult mice (Swiss or C57Bl6/J)
of both sexes (males n=10; females n=10) were perfused with cold heparinized saline
(15 ml) and, thereafter, with a solution containing 2% paraformaldehyde, 0.2% picric
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acid in 0.1 M sodium phosphate buffer pH 7.4 (150 ml). The brain and testes were
removed and left in the same fixative for 18 hours. Heads from E16 embryos (n=6)
were fixed by immersion over 18 hours. All tissues were rinsed frequently in Coons
buffer containing 20% sucrose before being frozen in Tissue-Tek (Miles Scientific,
Naperville, IL). Serial transversal cryostat brain sections were cut at 8 or 12 μm in
a cryomicrotome. Sections were collected on gelatin-coated slides and conserved at
–80°C before single- or double-label immunohistofluorescence methods were applied.
Briefly, a series of adjacent sections were incubated with primary antibodies to AMHR-
II (1:800) (Gouédard et al., 2000); BMPR-II (1:100, Sc-5682 SantaCruz), type IV
collagen (1:250, 1340-01 SouthernBiotech), NeuN (1:500, Mab377 Chemicon) and
160-kDa Neurofilament Medium (1:400, ab39371 Abcam). The specificity of the
primary antibody against AMHR-II and of the secondary antibody was checked in
sections from tissues in which AMHR-II expression is known to be absent (kidney,
liver) and by using positive tissue samples incubated with either the secondary antibody
alone, or subjected to signal extinction experiments, i.e. the combination of primary
and secondary antibodies after pre-treatment with the recombinant protein used to
produce the AMHR-II antiserum (recombinant form of the extracellular domain of
human AMHR-II at 1 μg per ml of diluted antiserum at 1:800; data not shown).
Sections were incubated at room temperature (2 hours), in a solution of donkey F(ab)2
fragments raised against IgGs of the appropriate species and linked to fluorescein
isothiocyanate (FITC, green) or tetramethyl rhodamine isothiocyanate (TRITC, red)
(both 1:300, Jackson ImmunoResearch, West Grove, PA). Washed sections were
coverslipped with antifade medium containing, or not, DAPI, and images were
digitally captured using a Leica DM6000 microscope-coupled CoolSNAP camera
and visualized with Metavue software (Molecular Devices).
Excitotoxic neuronal death
Excitotoxicity was induced by a 24-hour exposure of neuronal cultures (14 DIV) to
NMDA (12.5 μM), in serum-free DMEM supplemented with 10 μM glycine.
Increasing concentrations of recombinant mouse AMH (1 and 10 ng/ml) were co-
applied with the excitotoxin and left in the bathing medium for 24 hours. Neuronal
death was quantified by measurement of the activity of lactate dehydrogenase (LDH),
using the cytotoxicity detection kit (Roche Diagnostics, Germany), released from
damaged cells into the bathing medium (Koh and Choi, 1987).
Excitotoxic lesions
Excitotoxic lesions were performed under isoflurane-induced anaesthesia in male
Swiss mice (25-30 g; Janvier, France). Striatal bilateral injections (coordinates: 0.5
mm posterior, ± 2.0 mm lateral, –3.0 mm ventral to the bregma) (Franklin and Paxinos,
1997) of 10 nmol NMDA (total volume of 0.3 μl) versus NMDA + AMH (10 nmol
of NMDA and 0.45 pg of AMH; total volume of 0.3 μl) were performed after placing
the animals under a stereotaxic frame. Solutions were injected by the use of a
micropipette made with hematologic micropipettes (calibrated at 15 mm/μl; assistant
ref 555/5; Hecht, Sondheim-Rhoen, Germany). The needle was removed 5 minutes
later.
Histological analysis of lesion volume
After 24 hours the mice were euthanized, and the brains were removed and frozen
in isopentane. Cryostat-cut coronal brain sections (20 μm) were collected and stained
with thionin. For volume analysis, one section out of every 10 was stained and
analyzed. Regions of interest were determined through the use of a stereotaxic atlas
for the mouse and an image analysis system (ImageJ) was used to measure the lesion,
which corresponded to the unstained area. Results are expressed as mean ± s.e.m.
Statistical analysis
Data are expressed as the mean ± s.d. or s.e.m. Data were first analyzed by using
the Kruskall-Wallis test, which is the nonparametric version of the ANOVA for more
than two groups for unpaired series, followed by post-hoc comparisons, by using the
Mann-Whitney’s test, which is the nonparametric version of the t-test.
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